Details

Autor(en) / Beteiligte

• Nakaya, Aya
• Tanaka, Hirokazu
• Yagi, Hideo
• Ohta, Kensuke
• Shibayama, Hirohiko
• Kohara, Takae
• Kanda, Junya
• Shindo, Maki
• Shimura, Yuji
• Kosugi, Satoru
• Kida, Toru
• Kaneko, Hitomi
• Imada, Kazunori
• Karasuno, Takahiro
• Matsuda, Mitsuhiro
• Iida, Masato
• Adachi, Yoko
• Fuchida, Shin-ichi
• Uoshima, Nobuhiko
• Uchiyama, Hitoji
• Takahashi, Ryoichi
• Matsui, Toshimitsu
• Wada, Katsuya
• Kiyota, Miki
• Shimazaki, Chihiro
• Hino, Masayuki
• Kuroda, Junya
• Kanakura, Yuzuru
• Takaori-Kondo, Akifumi
• Nomura, Shosaku
• Matsumura, Itaru

Titel

Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry

Ist Teil von

• International journal of hematology, 2020-11, Vol.112 (5), p.666-673

Ort / Verlag

Singapore: Springer Singapore

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• We retrospectively analyzed 51 patients with solitary plasmacytoma diagnosed from October 2002 to September 2018 from a cohort of 3575 patients with plasma cell dyscrasias registered in the Kansai Myeloma Forum. Twenty-seven patients had solitary bone plasmacytoma (SBP) and 24 had extramedullary plasmacytoma (EMP), with prevalence of 0.8% and 0.7%, respectively. The most frequent M protein was IgG (40%) in SBP, whereas non-secretory proteins were most frequent (50%) in EMP. Five-year overall survival was 78.2% in SBP and 80.8% in EMP ( P  = 0.894). Among patients with SBP, 44% progressed to MM with a median time of 10.5 months (2.4–93.3 months), whereas 8% of EMP patients progressed to MM with a median time of 18.6 months (13.0–24.2 months). The most frequent treatment was radiotherapy (41%) or observation (41%) in SBP, and chemotherapy (54%) in EMP. No statistically significant difference was observed upon univariate analysis of prognostic factors including age, sex, performance status, and IgG M protein. Our results suggest that there are biological differences between SBP and EMP in real-world settings.